Naveen Yarasi, MD
Psychiatry · Columbia, MONPI 1689804262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $544 and has fallen 95.3% since, to $25 in 2024.
Across 41 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$181
- AbbVie$161
- Teva Pharmaceuticals USA, Inc.$157
- Alkermes, Inc.$114
- Johnson & Johnson$113
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$66
- plus $108 from 4 others
What the payments were for
- Food & beverage$901100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $181 |
| AbbVie | 5 | $161 |
| Teva Pharmaceuticals USA, Inc. | 5 | $157 |
| Alkermes, Inc. | 6 | $114 |
| Johnson & Johnson | 6 | $113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $66 |
| Neurocrine Biosciences, Inc. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Indivior Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
How this compares
$901 in reported general payments places this provider in the 70th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylphenidate Hcl | 14 | $379 |
| Olanzapine | 25 | $297 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Columbia
- Joseph ParksColumbia$63K
- Agara ReddyColumbia$12K
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.